- Share
Burden of bacterial antimicrobial resistance in low-income and middle-income countries avertible by existing interventions: an evidence review and modelling analysis
Infectious diseases
Published: May 23, 2024
Date (DD-MM-YYYY)
01-06-2024 to 01-06-2026
Available on-demand until 1st June 2026
Cost
Free
Education type
Article
CPD subtype
On-demand
Description
National action plans enumerate many interventions as potential strategies to reduce the burden of bacterial antimicrobial resistance (AMR). However, knowledge of the benefits achievable by specific approaches is needed to inform policy making, especially in low-income and middle-income countries (LMICs) with substantial AMR burden and low health-care system capacity.
In a modelling analysis, we estimated that improving infection prevention and control programmes in LMIC health-care settings could prevent at least 337 000 (95% CI 250 200–465 200) AMR-associated deaths annually. Ensuring universal access to high-quality water, sanitation, and hygiene services would prevent 247 800 (160 000–337 800) AMR-associated deaths and paediatric vaccines 181 500 (153 400–206 800) AMR-associated deaths, from both direct prevention of resistant infections and reductions in antibiotic consumption. These estimates translate to prevention of 7·8% (5·6–11·0) of all AMR-associated mortality in LMICs by infection prevention and control, 5·7% (3·7–8·0) by water, sanitation, and hygiene, and 4·2% (3·4–5·1) by vaccination interventions.
Despite the continuing need for research and innovation to overcome limitations of existing approaches, our findings indicate that reducing global AMR burden by 10% by the year 2030 is achievable with existing interventions. Our results should guide investments in public health interventions with the greatest potential to reduce AMR burden.
Contact details
Email address
Telephone number
0207 424 4950

Elsevier Ltd
125 London Wall
London
EC2Y 5AS